Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

✍ Scribed by Shinobu Umemura; Goi Sakamoto; Hironobu Sasano; Hitoshi Tsuda; Futoshi Akiyama; Masafumi Kurosumi; Yutaka Tokuda; Toru Watanabe; Masakazu Toi; Tadashi Hasegawa; R. Yoshiyuki Osamura

• Publisher: Springer Japan
• Year: 2001
• Tongue: English
• Weight: 998 KB
• Volume: 8
• Category: Article
• ISSN: 1340-6868
• DOI: 10.1007/bf02967531